February 18, 1997Circulation
Effects of GP IIb/IIIa Receptor Monoclonal Antibody (7E3), Heparin, and Aspirin in an Ex Vivo Canine Arteriovenous Shunt Model of Stent Thrombosis
Why the study?
Does 7E3, heparin, or aspirin reduce stent thrombosis in an ex vivo canine arteriovenous shunt model?
Population
10 anesthetized dogs with an ex vivo arteriovenous shunt containing rough-surface slotted-tube nitinol…
Comparison
Intravenous murine 7E32, heparin, or aspirin vs Control (untreated)
Design
Preclinical
Follow-up
20 minutes
Authors
Discussion
Loading...
Member takes
Implication
Hypothesis-generating for GP IIb/IIIa blockade in high-shear stent thrombosis; leaves open translation beyond this canine model.
Structured PICO
Does 7E3, heparin, or aspirin reduce stent thrombosis in an ex vivo canine arteriovenous shunt model?
P
Population
10 anesthetized dogs with an ex vivo arteriovenous shunt containing rough-surface slotted-tube nitinol stents (n=72) expanded to 2 mm in diameter
I
Intervention
Intravenous murine 7E3 (Fab')2 (0.2, 0.4, and 0.8 mg/kg), heparin (100 U/kg), or aspirin (10 mg/kg)
C
Comparator
Control (untreated)
O
Outcome
Thrombus weight (stent thrombosis)surrogate
In a canine ex vivo model, the GP IIb/IIIa inhibitor 7E3 effectively prevented high-shear stent thrombosis, while heparin and aspirin did not.
Cite This Study
Makkar et al. (1997) studied this question.